News Sentiment

AMGN sentiment intelligence

Amgen Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - General Read-through group
Latest close 363.39 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-2.9% over one week, +2.3% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction -2.9% Price reacting lower
Trend fit Trend active 2.3% over four weeks
Fair value 24.9% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 28
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
MarketBeat 10
Ad Hoc News 5
simplywall.st 4
Investing.com 3
24/7 Wall St. 2
TradingView 2
Zacks 1

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 13
Regulatory and legal 3
Analyst action 3
Guidance 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
MarketBeat Direct company coverage

Wealthfront Advisers LLC Boosts Position in Amgen Inc. $AMGN

Wealthfront Advisers LLC increased its stake in Amgen Inc. by 10.1% in the first quarter, bringing its total holdings to 90,562 shares valued at approximately $31.9 million. This move is part of a broader trend of institutional investment, as hedge funds and other institutions ow

Tone
Positive 73/100
Event
Earnings
Published
16 Jul 2026 11:02
Source
MarketBeat
MarketBeat Direct company coverage

D.A. Davidson & CO. Trims Stake in Amgen Inc. $AMGN

D.A. Davidson & CO. reduced its stake in Amgen Inc. by 2.7% in the first quarter, selling 6,632 shares and retaining 241,522 shares valued at approximately $84.98 million. Amgen exceeded first-quarter earnings expectations, reporting an EPS of $5.15 on revenue of $8.62 billion, a

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 08:20
Source
MarketBeat
MarketBeat Direct company coverage

Amgen Inc. $AMGN Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp decreased its stake in Amgen Inc. by 2.9% in the first quarter, selling over 113,000 shares, though still holding 3.79 million shares valued at $1.33 billion. Amgen reported strong Q1 earnings, surpassing revenue and EPS expectations. Analyst sentimen

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 07:23
Source
MarketBeat
Stock Traders Daily Direct company coverage

(AMGN) Price Dynamics and Execution-Aware Positioning

This article provides an analysis of Amgen Inc. (NASDAQ: AMGN) stock, highlighting a weak near-term sentiment but strong long-term outlook. It details specific AI-generated trading strategies including long, breakout, and short positions with defined entry points, targets, and st

Tone
Negative 38/100
Event
Regulatory and legal
Published
15 Jul 2026 22:07
Source
Stock Traders Daily
Trefis Direct company coverage

IBB ETF Holds Fewer Bets Than You Think

The iShares Biotechnology ETF (IBB) appears diversified with 249 stocks, but its effective holdings are closer to 35 equally weighted positions due to significant concentration. The top ten holdings account for 44% of its assets, with Vertex Pharmaceuticals, Amgen, and Gilead Sci

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 16:12
Source
Trefis
Simply Wall Street Direct company coverage

Amgen’s Tablet Recalls Test Its Quality Controls and Manufacturing Ambitions (AMGN)

Amgen recently initiated nationwide US recalls of certain Sensipar and Corlanor tablet lots due to FDA-identified manufacturing deviations and foreign substances. These Class II recalls raise concerns about Amgen's operational oversight and regulatory risk management, especially

Tone
Negative 38/100
Event
Regulatory and legal
Published
15 Jul 2026 15:45
Source
Simply Wall Street
MarketBeat Direct company coverage

Livforsakringsbolaget Skandia Omsesidigt Purchases 10,752 Shares of Amgen Inc. $AMGN

Livforsakringsbolaget Skandia Omsesidigt increased its stake in Amgen Inc. by 18.7% in the first quarter, now owning 68,130 shares valued at $23.95 million. This makes Amgen its 22nd biggest holding, constituting 1.0% of its portfolio. Other institutional investors also adjusted

Tone
Positive 62/100
Event
Earnings
Published
15 Jul 2026 10:36
Source
MarketBeat
MarketBeat Direct company coverage

AMG National Trust Bank Has $4.59 Million Stock Position in Amgen Inc. $AMGN

AMG National Trust Bank significantly increased its stake in Amgen Inc. to $4.59 million, holding 13,034 shares by the first quarter's end. This move follows Amgen's strong first-quarter financial performance, which exceeded revenue and EPS expectations. Despite positive analyst

Tone
Positive 60/100
Event
Earnings
Published
15 Jul 2026 07:41
Source
MarketBeat
Market source Direct company coverage

Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know

Amgen (AMGN) stock fell by 1.44% in the latest trading session, underperforming the broader market. The company's upcoming earnings report projects a 7.81% drop in EPS year-over-year, despite an expected 2.9% revenue increase. Amgen currently holds a Zacks Rank of #3 (Hold) and t

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 21:50
Source
Market source
MedCity News Direct company coverage

After Antibiotic Approval, Spero Pivots to Immunology Aiming to Rival an Amgen Asset

Spero Therapeutics, fresh off FDA approval for its antibiotic Utebzi, is pivoting into immunology with a new Phase 2-ready drug, SP001. This monoclonal antibody, licensed from Innovent Biologics, targets CD40 ligand and will be developed for immunoglobulin G4-related disease (IgG

Tone
Positive 67/100
Event
Regulatory and legal
Published
14 Jul 2026 20:22
Source
MedCity News
MarketWatch Direct company coverage

Amgen Inc. stock outperforms competitors despite losses on the day

Amgen Inc. (AMGN) shares fell by 1.44% to $355.25 on Tuesday, marking its fifth consecutive day of losses, despite a favorable trading session for the broader market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains.

Tone
Negative 38/100
Event
Market update
Published
14 Jul 2026 16:34
Source
MarketWatch
24/7 Wall St. Direct company coverage

Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen

This article contrasts Pfizer and Amgen, arguing that Pfizer offers a better investment in oncology due to its successful integration of Seagen and existing revenue streams. Pfizer trades at a lower forward P/E of 8x with a substantial 7% dividend yield, while Amgen faces signifi

Tone
Negative 37/100
Event
Earnings
Published
14 Jul 2026 15:51
Source
24/7 Wall St.
Law360 Direct company coverage

Amgen Colo. Win May Chill States' Push To Cap Drug Prices

A recent victory for Amgen in Colorado could slow down states' efforts to set limits on prescription drug prices. Colorado was the first state to announce a price cap on a medication, marking a significant step in state-level drug regulation. The full article is behind a paywall,

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 12:58
Source
Law360
MarketBeat Direct company coverage

Amgen Inc. $AMGN Shares Sold by Mattern Capital Management LLC

Mattern Capital Management LLC reduced its stake in Amgen Inc. by 30.9% in the first quarter, selling 10,686 shares and retaining 23,890. Despite this, Amgen exceeded Q1 earnings expectations with EPS of $5.15 and reaffirmed its FY2026 EPS guidance. While analysts maintain a "Hol

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 10:21
Source
MarketBeat
Yahoo! Finance Canada Direct company coverage

HRMY vs. AMGN: Which Stock Is the Better Value Option?

This article from Zacks Equity Research compares Harmony Biosciences Holdings, Inc. (HRMY) and Amgen (AMGN) to determine which is a better value stock. Utilizing the Zacks Rank and Style Scores, particularly the Value category, the analysis concludes that HRMY is the superior val

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 08:40
Source
Yahoo! Finance Canada
MarketBeat Direct company coverage

Calamos Advisors LLC Buys 3,648 Shares of Amgen Inc. $AMGN

Calamos Advisors LLC increased its stake in Amgen Inc. by 5.1% in the first quarter, purchasing an additional 3,648 shares which brought their total holding to 75,496 shares valued at approximately $26.6 million. Wall Street analysts have a "Hold" consensus rating for Amgen with

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 08:21
Source
MarketBeat
Market source Direct company coverage

Advancements in CKD Care: How New Therapies from AstraZeneca, Johnson & Johnson, Novartis, Bayer, and Amgen Are Changing the Landscape

The late stage Chronic Kidney Disease (CKD) Therapeutics Market, valued at $13.02 billion in 2025, is projected to reach $25.20 billion by 2032, growing at a CAGR of 9.88%. This growth is driven by technological advancements, a shift towards integrated cardio-renal-metabolic stra

Tone
Positive 67/100
Event
Market update
Published
14 Jul 2026 08:15
Source
Market source
TradingView Direct company coverage

AMGD Bond Profile — Key Metrics

This article provides a bond profile for Amgen Inc.'s AMGD bond (4.2% 22-FEB-2052). It details key metrics such as the issuer, issue date, maturity date, outstanding amount, face value, minimum denomination, and coupon rate. Amgen Inc. is identified as a biotechnology company fou

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 07:37
Source
TradingView
MarketBeat Direct company coverage

Bleakley Financial Group LLC Purchases 3,526 Shares of Amgen Inc. $AMGN

Bleakley Financial Group LLC increased its stake in Amgen Inc. by 12.0% in the first quarter, adding 3,526 shares and bringing its total holding to 32,930 shares valued at $11.6 million. This aligns with high institutional interest in Amgen, where 76.5% of shares are institutiona

Tone
Positive 66/100
Event
Earnings
Published
14 Jul 2026 07:33
Source
MarketBeat